Gilman T, Owens W, George C, Metzel L, Vitela M, Ferreira L
J Pharmacol Exp Ther. 2019; 371(2):268-277.
PMID: 31481515
PMC: 6795746.
DOI: 10.1124/jpet.119.260794.
Igoumenou A, Turri M, Din R, Gordon H
BMJ Case Rep. 2011; 2009.
PMID: 22171235
PMC: 3029562.
DOI: 10.1136/bcr.04.2009.1736.
Khakimova G, Kozina E, Sapronova A, Ugrumov M
Dokl Biol Sci. 2011; 440:284-6.
PMID: 22134811
DOI: 10.1134/S0012496611050231.
van Vliet S, Jongsma M, Vanwersch R, Olivier B, Philippens I
Psychopharmacology (Berl). 2006; 185(4):433-40.
PMID: 16550386
DOI: 10.1007/s00213-006-0340-4.
Stone E, Quartermain D
Psychopharmacology (Berl). 2005; 178(2-3):109-14.
PMID: 15645218
DOI: 10.1007/s00213-004-2125-y.
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
Hill M, Brotchie J
Br J Pharmacol. 1999; 128(7):1577-85.
PMID: 10602339
PMC: 1571785.
DOI: 10.1038/sj.bjp.0702943.
Clonidine: attenuation of sedative action by facilitated central noradrenergic neurotransmission.
Strombom U, Svensson T
J Neural Transm. 1980; 47(1):29-39.
PMID: 7359121
DOI: 10.1007/BF01256637.
A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.
Feenstra M, Sumners C, Goedemoed J, DE VRIES J, Rollema H, Horn A
Naunyn Schmiedebergs Arch Pharmacol. 1983; 324(2):108-15.
PMID: 6646238
DOI: 10.1007/BF00497015.
Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively.
ANDEN N, Thornstrom U
Naunyn Schmiedebergs Arch Pharmacol. 1982; 321(2):100-4.
PMID: 6296699
DOI: 10.1007/BF00518475.
Selective blockade of brain alpha 2-autoreceptors by yohimbine: effects on motor activity and on turnover of noradrenaline and dopamine.
ANDEN N, Pauksens K, Svensson K
J Neural Transm. 1982; 55(2):111-20.
PMID: 6294237
DOI: 10.1007/BF01243754.
A behavioural study of the changes in the central nervous system of mice after subchronic treatment with the selective dopamine autoreceptor agonist 3-PPP (dl-3-[3-hydroxyphenyl]-N-n-propylpiperidine).
Jackson D, Carlsson A, Hjorth S, Lindberg P
J Neural Transm. 1982; 53(4):233-45.
PMID: 6286867
DOI: 10.1007/BF01252035.
Effects of propranolol on the locomotor stimulation induced by activation of postsynaptic catecholamine receptors.
Hallberg H, ALMGREN O, Engel J, Jonason J
Psychopharmacology (Berl). 1981; 72(3):227-31.
PMID: 6261288
DOI: 10.1007/BF00431821.
Time course of rat motility response to apomorphine: a simple model for studying preferential blockade of brain dopamine receptors mediating sedation.
Montanaro N, Vaccheri A, DallOlio R, Gandolfi O
Psychopharmacology (Berl). 1983; 81(3):214-9.
PMID: 6139839
DOI: 10.1007/BF00427264.
alpha-Adrenergic agents. 3. Behavioral effects of 2-aminotetralins.
HOLZ W, Hieble J, Gill C, DeMarinis R, Pendleton R
Psychopharmacology (Berl). 1982; 77(3):259-67.
PMID: 6126908
DOI: 10.1007/BF00464577.
Modulation of motor activity by alpha 1- and alpha 2-adrenoceptor stimulation in mice.
Pichler L, KOBINGER W
Naunyn Schmiedebergs Arch Pharmacol. 1981; 317(2):180-2.
PMID: 6117802
DOI: 10.1007/BF00500078.
Ethanol and caffeine: a complex interaction with respect to locomotor activity and central catecholamines.
WALDECK B
Psychopharmacologia. 1974; 36(3):209-20.
PMID: 4846326
DOI: 10.1007/BF00421803.
Sensitization by caffeine of central catecholamine receptors.
WALDECK B
J Neural Transm. 1973; 34(1):61-72.
PMID: 4714594
DOI: 10.1007/BF01244827.
Adrenergic receptor blocking agents: effects on central noradrenaline and dopamine receptors and on motor activity.
ANDEN N, Strombom U
Psychopharmacologia. 1974; 38(2):91-103.
PMID: 4533319
DOI: 10.1007/BF00426104.
Modification of the caffeine-induced locomotor stimulation by a cholinergic mechanism.
WALDECK B
J Neural Transm. 1974; 35(3):197-205.
PMID: 4427109
DOI: 10.1007/BF01258951.
DL-threo-DOPS as a precursor of noradrenaline.
Reches A, Jackson-Lewis V, Fahn S
Naunyn Schmiedebergs Arch Pharmacol. 1985; 331(2-3):202-8.
PMID: 3937060
DOI: 10.1007/BF00634239.